**BREAKING NEWS** Our crowdfunding campaign is LIVE! To have a chance of investing in our cutting-edge diagnostic technology, watch our video and find out more at backtowork24

To KNOW NOW

That’s what patients and physicians want.

Immediate access to accurate diagnostic tests that directly impact the lives of patients and allow healthcare providers to make informed and effective clinical decisions.

How it WorksInvest in dianax

Your chance to invest ...
Crowdfunding campaign is live!

With dianax lab-on-a-chip, POINT OF NEED testing is becoming a reality and thanks to our NEW CROWDFUNDING* CAMPAIGN, you could be part of its future.

Diagnostics in the palm of your hand … from a drop of blood to final results in under five minutes.

Microfluidics-based POINT OF NEED testing is one of the fastest-growing segments of the in-vitro diagnostics market and integral to the diagnosis, management and monitoring of many chronic diseases, including diabetes. Freeing people from endless trips to the doctor or hospital and empowering them to monitor their own health ‘on the go’ has the potential to not only change lives, but also improve patient outcomes.

Our aim is to capture a significant share of this large and growing market.

 

A minimum €500 investment is all it takes**… to sign up or find out more, visit backtowork24

#crowdfunding
#crowdfundingcampaign
#backtowork
#backtowork24
#campaign #platform

*Equity crowdfunding is a form of investment that allows a group of investors to finance start-ups and SMEs through online portals authorized by Consob, providing a loan in exchange for company shares of the same company. For Italian tax resident investors, tax breaks are envisaged of up to 40% of the amount invested in innovative start-ups and SMEs.

**Information found on the Backtowork24 portal is not subject to approval by Consob (Italian authority for the supervision of financial markets). The issuer is solely responsible for the completeness and truthfulness of the data and information provided. Please note that investment in financial instruments issued by innovative start-ups is illiquid and characterized as very high risk.

 

No.1 start-up at BigBooster International Start-Up Acceleration Program

dianax are proud to announce being nominated No.1 out of the 250 startups participating from Europe, Middle East and Africa.

dianax is making POINT OF NEED testing a reality.
Our revolutionary lab-on-a-chip* puts diagnostics in the palm of your hand – literally – by working in synergy with your smartphone.

By bringing laboratory-grade disease screening, diagnosis and monitoring to the patient, dianax is taking diagnostics straight to the POINT OF NEED. For the first time ever – patients and physicians will be able to KNOW NOW.

R
Patients NEED easy and convenient ways to monitor their health ‘on the go’. Empowering patients to be a custodian of their own health has been shown to improve health outcomes1

R
Physicians NEED fast, reliable and accurate blood test results in order to determine the best course of action2

R
Payors NEED affordable diagnostics to support the wider shift towards decentralization, value-based healthcare and personalized (patient-centric) care3


There is no time to wait:
the time is NOW

We are seeing a tectonic shift in healthcare infrastructure as we know it, powered by the smartphone revolution, and dianax is at the cutting-edge of mobile diagnostic transformation. Our device may be tiny but the implications are immense. While HbA1c-glycated hemoglobin blood testing for diabetes is our primary focus, the dianax lab-on-a-chip can test any protein extracted from bodily fluids (blood, urine, saliva), and so has the potential to transform diagnostic testing across a number of therapy areas.

We believe that rapid detection combined with informed decision-making will optimize treatment and improve patient outcomes. From expediting the screening, diagnosis and management of chronic diseases, such as diabetes or anemia, to detecting bacterial respiratory infections to prevent overuse or misuse of antibiotics, dianax will bring fast, reliable and affordable diagnostics to the POINT OF NEEDanytime, anywhere, for anyone.

We understand that when it comes to people’s health, to KNOW NOW really does matter.

Across the world …

425 million

diabetics

1 in 2

remains undiagnosed4

2 billion

people have iron deficiency anemia5

700,000

people are killed each year by antibiotic resistant infection6

Our Investors

The ongoing development of dianax lab-on-a-chip has been made possible thanks to investment from multiple sources.

Horizon 2020

We are indebted to those in the European Commission who recognized early on the extraordinary potential of our technology in changing the face of diagnostic testing and awarded a significant grant through their Horizon 2020 Program. This flagship initiative is designed to facilitate ‘breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market’, and we are committed to doing just that.

*Products/devices are under development but not yet approved for use. For investigational use only. 

  1. Yole Développement. Point-of-Need Testing: Application of Microfluidic Technologies 2016 report. September 2016.
  2. Larsson A, et al. Ups J Med Sci. 2015;120(1):1–10 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389002/ [Accessed 10 Dec 2017]
  3. European Steering Group for Sustainable Healthcare
    https://www.sustainable-healthcare.com/?gclid=EAIaIQobChMIx_DavY3_1wIVwbftCh3JtAIrEAAYASAAEgKq_vD_BwE [Accessed 10 Dec 2017]
  4.  International Diabetes Federation (IDF) Diabetes Atlas – 8th Edition 2017 http://www.diabetesatlas.org [Accessed 25 January 2018]
  5. World Health Organization. Micronutrient deficiencies. http://www.who.int/nutrition/topics/ida/en/  [Accessed 25 January 2018]
  6. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final Report and recommendations.
    https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Accessed 25 January 2018]